Skip to content
Exclusive CEO Interviews

Press Release

Make us preferred on Google
Perspective Therapeutics Announces Pricing of $175 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Perspective Therapeutics Announces Pricing of $175 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

✨ Onyx Summary Perspective Therapeutics priced an underwritten public offering of common stock and pre-funded warrants expected to raise approximately $175 million in gross proceeds. The financing strengthens the company’s balance sheet to advance its radiopharmaceutical pipeline, expand manufacturing capabilities, and support general corporate purposes. SEATTLE, Feb. 02, 2026 – Perspective

Lexicon Announces Proposed Public Offering of Common Stock

Lexicon Announces Proposed Public Offering of Common Stock

✨ Onyx Summary Lexicon Pharmaceuticals commenced an underwritten public offering of common stock, with Jefferies and Piper Sandler acting as joint book-running managers, alongside a concurrent private placement with an affiliate of Invus under its preemptive rights. The financing is intended to support continued research and development of Lexicon’s pipeline

Opentrons Global Robotics Chief, James Atwood, Named Chief Executive Officer

Opentrons Global Robotics Chief, James Atwood, Named Chief Executive Officer

✨ Onyx Summary Opentrons Labworks promoted James Atwood to Chief Executive Officer, formalizing his leadership after overseeing growth to more than 10,000 robotic systems deployed across academic and biopharma laboratories worldwide. The move reinforces Opentrons’ strategy to connect AI-driven discovery with physical lab execution, highlighted by its role as an

Cellares Raises $257 Million Series D Led by BlackRock and Eclipse to Industrialize Global Cell Therapy Manufacturing with Breakthrough Automation

Cellares Raises $257 Million Series D Led by BlackRock and Eclipse to Industrialize Global Cell Therapy Manufacturing with Breakthrough Automation

✨ Onyx Summary Cellares raised $257 million in a Series D financing co-led by investment funds managed by BlackRock and Eclipse, bringing total capital to $612 million to fund the global rollout of automated IDMO Smart Factories and support commercial-scale cell therapy manufacturing beginning in 2027. The financing positions Cellares to

ImmunityBio Reports Median Overall Survival Not Yet Reached and Lymphopenia Reversed in Recurrent Glioblastoma Patients Receiving ANKTIVA® Plus CAR-NK, Chemo-Free Therapy

ImmunityBio Reports Median Overall Survival Not Yet Reached and Lymphopenia Reversed in Recurrent Glioblastoma Patients Receiving ANKTIVA® Plus CAR-NK, Chemo-Free Therapy

✨ Onyx Summary ImmunityBio reported updated Phase 2 data from its QUILT-3.078 study showing that 19 of 23 patients with recurrent or progressive glioblastoma remain alive, with median overall survival not yet reached, following a chemotherapy-free combination immunotherapy regimen. The results suggest potential survival beyond historical benchmarks in a heavily

Guardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for BRAFTOVI® (encorafenib) Combination in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer

Guardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for BRAFTOVI® (encorafenib) Combination in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer

✨ Onyx Summary Guardant Health announced that the U.S. Food and Drug Administration approved Guardant360 CDx as a companion diagnostic to identify patients with BRAF V600E–mutant metastatic colorectal cancer eligible for treatment with BRAFTOVI in combination therapy. Supported by Phase 3 BREAKWATER trial data, the approval expands non-invasive access

Legend Biotech to Present CARVYKTI® Data at 2026 Tandem Meetings Reinforcing Growing Evidence Supporting Earlier Use

Legend Biotech to Present CARVYKTI® Data at 2026 Tandem Meetings Reinforcing Growing Evidence Supporting Earlier Use

✨ Onyx Summary Legend Biotech will present six posters at the 2026 ASTCT/CIBMTR Tandem Meetings highlighting additional clinical and real-world analyses for CARVYKTI in multiple myeloma, including data on neurologic events, bridging therapy, manufacturing outcomes, and long-term progression-free survival. The updates build the evidence base for optimizing CARVYKTI use—particularly

Lexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA For Pilavapadin in the Treatment of Diabetic Peripheral Neuropathic Pain

Lexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA For Pilavapadin in the Treatment of Diabetic Peripheral Neuropathic Pain

✨ Onyx Summary Lexicon Pharmaceuticals completed a successful End-of-Phase 2 meeting with the U.S. Food and Drug Administration for pilavapadin in diabetic peripheral neuropathic pain, with the FDA raising no objections to advancing the program into Phase 3 registrational studies. The outcome clears a regulatory path toward late-stage development of

Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock

Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock

✨ Onyx Summary Ocugen priced an underwritten public offering of 15 million shares at $1.50 per share, raising $22.5 million in gross proceeds to support general corporate purposes and operations. Led by RTW Investments, the financing strengthens Ocugen’s balance sheet as it advances its gene therapy programs for

Behind the Breakthrough: MassBio’s 2026 State of Possible Conference

Behind the Breakthrough: MassBio’s 2026 State of Possible Conference

✨ Onyx Summary MassBio outlined the agenda for its 2026 State of Possible Conference on March 26 in Boston, convening senior biotech CEOs, investors, policymakers, and ecosystem leaders to examine how scientific discovery translates into patient impact amid long development timelines and shifting economic pressures. The program features keynote leaders including